Treatment of triple-negative breast cancer (TNBC) is limited by a lack of effective molecular targeted therapies. Recent studies have identified metabolic alterations in cancer cells that can be targeted to improve responses to standard-of-care chemotherapy regimens. We found that exposure of TNBC cells to cytotoxic chemotherapy drugs leads to alterations in arginine and polyamine metabolites due to a reduction in the levels and activity of a rate-limiting polyamine biosynthetic enzyme ornithine decarboxylase (ODC). The reduction in ODC was mediated by its negative regulator, antizyme, targeting ODC to the proteasome for degradation. Treatment with the ODC inhibitor DFMO sensitized TNBC cells to chemotherapy, but this was not observed in receptor-positive breast cancer cells. Moreover, TNBC cell lines showed greater sensitivity to single-agent DFMO, and ODC levels were elevated in TNBC patient samples. Alterations in polyamine metabolism in response to chemotherapy, as well as preferential sensitization of TNBC cells to chemotherapy by DFMO, suggest that ODC may be a targetable metabolic vulnerability in TNBC.
Introduction
In the past two decades, a renewed interest in tumor metabolism has led to the identification of novel therapeutic vulnerabilities in a variety of cancers (1, 2) . This is especially promising for tumor types that lack effective targeted therapies, such as triple-negative breast cancer (TNBC). TNBC comprises 15-20% of breast cancer cases, but accounts for a disproportionately high percentage of breast cancer-related deaths (3) . This is in part due to a lack of targeted therapies for this molecular subtype of breast cancer, and the standard of care treatment for TNBC remains genotoxic chemotherapy. Previous studies have identified metabolic vulnerabilities in breast cancer cells including nucleotide metabolism, glutathione biosynthesis and glutamine metabolism that improve response to chemotherapy drugs (4) (5) (6) .
The amino acid arginine has been extensively studied in the context of cancer metabolism and has been suggested to contribute to the development and progression of cancer (7) . Arginine is involved in numerous cell growth control processes, including protein synthesis, nitric oxide (NO) production and polyamine biosynthesis, as well as cellular energy production via the TCA cycle (8) . Furthermore, arginine plays an important role in the immune system, as it is required for full activation of natural killer and T-cells (9, 10) . A number of studies aimed at targeting arginine metabolism have focused on arginine auxotroph tumors, since they are sensitive to arginine depletion (11, 12) . However, less than 10% of breast tumors lack the rate-limiting arginine synthesis enzyme argininosuccinate synthase (ASS1) (13) . Therefore, additional branches of arginine metabolism may be altered in breast cancer and represent potential metabolic vulnerabilities.
The polyamines putrescine, spermidine and spermine are cationic molecules that are synthesized from arginine following its conversion to ornithine and are essential for eukaryotic cell growth and differentiation (14) . Functions attributed to polyamines include binding to nucleic acids and chromatin, stabilizing cellular membranes, regulating ion channels and scavenging free radicals (15) . Polyamines can form hydrogen bonds with anions, such as nucleic acids, proteins and phospholipids, and lead to condensation of DNA and chromatin (16, 17) . Ornithine decarboxylase (ODC), the first rate-limiting enzyme in polyamine synthesis, is regulated transcriptionally, translationally, and post-translationally (18). Moreover, ODC levels and activity are altered in response to extracellular stimuli such as hormones and growth factors, as well as changes in intracellular free polyamine levels (15, 18, 19) .
Elevated polyamine levels have been detected in tumors, including breast tumors, and increased polyamine synthesis has been shown to promote tumor initiation and growth (14, 17) .
Combined inhibition of polyamine uptake and synthesis results in antiproliferative effects in breast cancer cell lines and mouse models, suggesting that targeting polyamine metabolism may be therapeutically effective in breast cancer patients (20, 21) . Although drugs that target polyamine metabolism have not yet been approved for therapeutic use in cancer, clinical trials using polyamine uptake and synthesis inhibitors are underway for a number of indications, although to date none in breast cancer (22) . Here we show that polyamine synthesis is suppressed in response to DNA damaging chemotherapy through the proteasomal degradation of ODC. Further decreasing the polyamine pool using ODC inhibitors increases the sensitivity of TNBC to standard-of-care genotoxic drugs.
Results

Genotoxic chemotherapy alters levels of polyamines and related metabolites in TNBC
To evaluate the alterations in intracellular metabolites in breast cancer cells exposed to genotoxic chemotherapy drugs, we measured the levels of polar metabolites in MDA-MB-468 and SUM-159PT TNBC cells following treatment with cisplatin or doxorubicin for 8, 24, or 48 hours. We first determined the concentration of both drugs required for the induction of DNA damage as measured by increased H2AX phosphorylation, while remaining below the IC50 for cell death (Fig. 1, A and B) . Based on this analysis, both cell lines were treated with 0.5 µM doxorubicin and 2.5 µM cisplatin, and targeted metabolomics profiling of 186 metabolites was performed using LC-MS/MS (Figs. 1C and S1). Increases in pyrimidine nucleotides were observed in response to DNA damage, consistent with previous reports (4).
We focused on metabolites involved in arginine metabolism, including the urea cycle, nitric oxide (NO) cycle, polyamine metabolism, proline metabolism and creatine synthesis ( Fig.   2A ). Twelve metabolites involved in arginine metabolism were detected by our LC-MS/MS platform (Fig. 2, A and B) . In response to genotoxic drugs, the most upregulated metabolite in arginine metabolism was ornithine, and the most decreased was S-adenosyl methionine (SAM) ( Fig. 2, B and C). Ornithine can be synthesized either from arginine by arginase, or from glutamine via ornithine aminotransferase, although previous reports have shown that in transformed cells, ornithine is derived exclusively from arginine (23) . In MDA-MB-468 and SUM-159PT TNBC cells, carbons from 13 C6-arginine, but not 13 C5-glutamine, were incorporated into ornithine, even though both exogenous 13 C6-arginine and 13 C5-glutamine efficiently labeled their respective intracellular pools, and this was unaffected in doxorubicin-treated cells ( Fig. 2D ).
Since both ornithine and SAM are required for the synthesis of polyamines, but polyamines were not detectable on our LC-MS/MS platform, we measured polyamine levels by conventional HPLC analysis ( Fig. 2E ). After 48 hours of exposure to genotoxic drugs, putrescine and spermidine were significantly decreased by doxorubicin, and also decreased in response to cisplatin. These data suggest that genotoxic drugs alter arginine metabolites involved in polyamine synthesis in TNBC cells.
Chemotherapy decreases levels and activity of ornithine decarboxylase
We reasoned that the altered levels of polyamine metabolites were due to changes in enzyme levels or activity in response to chemotherapy exposure. ODC catalyzes the first rate-limiting step in polyamine synthesis, specifically the conversion of ornithine to putrescine ( Fig. 2A ).
Decreased ODC levels or activity could account for the observed decreases in polyamines and increases in ornithine ( Fig. 2 , C and E), though ornithine could also be elevated by increased activity of arginase II (ARG2) ( Fig. 2A ). Cisplatin and doxorubicin increased total ODC protein at early timepoints (8 hours), consistent with a stress response (22) , but led to decreased ODC and increased ARG2 at later timepoints (Fig. 3A ). This pattern of ODC expression was also observed in multiple TNBC and non-TNBC breast cancer cell lines ( Fig. 3, B-D) . By contrast, alterations in ARG2 expression were not significant across all lines. We also confirmed a concomitant decrease in ODC activity after 24 and 48 hours of exposure to cisplatin or doxorubicin ( Fig. 4A ). A significant decrease in putrescine at 72 and 96 hours was also observed, in addition to significantly reduced spermidine after 96 hours of doxorubicin treatment and a time-dependent decreasing trend in spermine concentration ( Fig. 4B ).
To investigate the mechanism by which ODC protein and activity are decreased following chemotherapy exposure, we first evaluated transcriptional regulation of ODC1, which is a well-characterized target of c-Myc (24) . Depletion of c-Myc using siRNA did not alter the overall ODC response to chemotherapy ( Fig. 5A ), although ODC1 transcript was increased following chemotherapy exposure ( Fig. 5B ). ODC protein is post-translationally regulated by the activity of antizyme, which binds ODC to promote its ubiquitin-independent degradation by the 26S proteasome (25) . Pre-treatment with the proteasome inhibitor MG132 rescued the decrease in ODC protein following doxorubicin exposure ( Fig. 5C ). siRNA against antizyme decreased the corresponding transcript of OAZ1 by over 80% (Fig. 5D ) and blocked the decrease in ODC in response to doxorubicin ( Fig. 5E ). Therefore, it appears that genotoxic drugs decrease polyamines by reducing ODC protein and activity, possibly through the negative regulator antizyme.
Targeting polyamine synthesis increases sensitivity to chemotherapy
Polyamines promote cell cycle progression (26) , and depletion of ODC or polyamines induces cell cycle arrest at the G2/M phase (27) (28) (29) , where cells are more sensitive to DNA damage induced by cisplatin and doxorubicin (30) (31) (32) . Since we observed a decrease in polyamines and ODC activity following chemotherapy treatment, we reasoned that targeting ODC to further decrease polyamines could increase tumor cell killing. Treatment with the irreversible suicide inhibitor of ODC, α-difluoromethylornithine (DFMO), sensitized both MDA-MB-468 and SUM-159PT cells to doxorubicin ( Fig. 6A ). Addition of exogenous putrescine or spermidine did not rescue this sensitization (Fig. 6B) . A previous study reported that DFMO can decrease colon cancer cell growth by increasing polyamine recycling, leading to a futile cycle that depletes SAM and nucleotides, and that this effect can be rescued by exogenous thymidine (33) . However, in TNBC cells, thymidine addition did not rescue the sensitization to doxorubicin by DFMO ( Fig.   6C ). Treatment of MDA-MB-468 cells with the arginase inhibitor Nω-hydroxy-nor-arginine (NOHA) also increased sensitivity to doxorubicin ( Fig. 6D ), consistent with its ability to decrease polyamine levels (34, 35) .
To confirm the on-target effects of DFMO, we measured polyamine levels after 72 hours of treatment with DFMO. As expected, putrescine was decreased in MDA-MB-468 cells and undetectable in SUM-159PT cells, and spermidine was also reduced ( Fig. 6E ). To further investigate the effects of DFMO, we measured polar metabolites following exposure to DFMO ( Fig. S2 ). The putrescine metabolite 4-aminobutyrate was significantly decreased, and other metabolites related to nucleotide, one-carbon, and amino acid metabolism were also decreased ( Fig. 6F ). This suggests that these metabolites must be replenished to reverse the effects of DFMO and resulting sensitization to doxorubicin.
Across a panel of breast cancer cell lines representing both luminal A, HER2 + and TNBC
subtypes, we observed that all TNBC cell lines tested were sensitized to doxorubicin by pretreatment with DFMO, whereas most non-TNBC lines were not (Fig. 7, A and B) . Overall, cell lines that displayed the greatest sensitization to doxorubicin by DFMO are classified as TNBC ( Fig. 7C ). These findings prompted us to determine whether there exists an intrinsic property of TNBC that makes this molecular subtype of breast cancer more dependent on ODC.
Ornithine decarboxylase is a metabolic vulnerability in TNBC
To investigate the role of arginine and polyamine metabolism in TNBC, we queried the alterations in the transcripts of 1,270 genes in the KEGG 'metabolic pathways' (KEGG:hsa01100) in the METABRIC breast cancer dataset (36) (37) (38) . Of these transcripts, 1, 134 were analyzed in 1,904 tumors ( Fig. S3 ). We found that ODC1 is one of the top 5 most significantly enriched transcripts in TNBC samples (Fig. 8, A and B) . ODC1 was also enriched in TNBC patient samples from the TCGA provisional breast dataset ( Fig. 8C ). Although we did not observe the same trends for transcript and protein levels of ODC in response to chemotherapy ( Fig. 3A and Fig. 5B ), baseline transcript and protein levels positively correlated in the TCGA breast samples for which protein mass spectrometry data is available ( Fig. 8D ). ODC1 transcript levels were also enriched in the basal subtype of breast cancer, which is commonly associated with TNBC ( Fig. 8E) (39) .
The increased ODC1 levels in TNBC could be due to changes in ODC1 copy number, since the average ODC1 copy number was higher in TNBC compared to non-TNBC ( Fig. 8F ).
MYC amplification also correlated with increased ODC1 transcript in TNBC, but not in non-TNBC patient samples ( Fig. 8G ). We also observed decreased copy number and transcript levels for multiple antizyme genes and transcripts (OAZ1/2/3) in TNBC (Fig. 8, H and I) , as well as increased copy number of AZI gene AZIN1 (Fig. 8J) (40) .
Enrichment of ODC1 transcript was also observed in TNBC cells lines according to the Cancer Cell Line Encyclopedia (41) and confirmed by RT-PCR analysis of select breast cancer cell lines (Fig. 9, A and B) , consistent with a previous study of four breast cancer cell lines (42) .
A trend towards higher baseline protein expression of ODC in TNBC cells was also observed 
Discussion
Advances in understanding the reprogramming of metabolic pathways in human cancers have led to the identification of druggable targets that have served as the basis for clinical trials, with the goal of targeting tumor-specific metabolic vulnerabilities. In breast cancer, alterations in glutathione, nucleotide and glutamine metabolism occur in response to genotoxic chemotherapy (4) (5) (6) . In the present study, we investigated changes in arginine and polyamine-related metabolites in response to genotoxic chemotherapy in TNBC cells. We found that genotoxic drugs decrease ODC levels and activity, with a corresponding reduction in the polyamines putrescine and spermidine. ODC expression is increased in TNBC patient samples and cell lines, to the extent that targeting ODC with the inhibitor DFMO sensitizes TNBC cells to doxorubicin.
TNBC cell lines exposed to chemotherapy showed a significant decrease in the expression and activity of ODC ( Fig. 3 and 4 ). This decrease was not due to alterations in transcript levels nor is it mediated by c-Myc, a major transcriptional regulator of ODC (43) .
Instead, reduced ODC expression in response to chemotherapy was mediated through degradation by the 26S proteasome ( Fig. 5 ). ODC has a half-life of 10-30 minutes, one of the shortest of any mammalian protein (44) . ODC turnover is regulated by binding to antizyme, a protein that binds ODC and targets it for destruction by non-ubiquitin mediated degradation (25) .
Antizyme itself is translationally regulated through the binding of polyamines to its transcript OAZ1, thereby inducing a +1 ribosomal frameshift (25) . Thus, antizyme levels are increased when intracellular polyamine concentrations are elevated. The observed initial increases in polyamines after 8 hours of chemotherapy exposure may be sufficient to increase translation of OAZ1 and subsequently increase antizyme expression ( Fig. 3 ), resulting in ODC degradation.
One previous study demonstrated that doxorubicin increases antizyme expression mediated by c-Jun, though the mechanistic basis was not determined (45) . An alternative mechanism that could account for ODC regulation is increased antizyme binding to ODC in response to chemotherapy. Moreover, since antizyme inhibitor (AZI) binds antizyme with a greater affinity than ODC, thereby protecting ODC from antizyme-mediated degradation (15, 24) , decreased AZI would free antizyme to bind ODC. Future studies are necessary to address which of these mechanisms is responsible for regulation of ODC in response to chemotherapy.
Treatment with the ODC inhibitor DFMO sensitizes TNBC cells to chemotherapy drugs, consistent with previous observations that polyamines bind and stabilize DNA and in turn occlude genotoxic agents (46) . Conversely, depleting polyamines increases DNA damage and induces cell cycle arrest (47) (48) (49) . Depletion of ODC or polyamines induces arrest in G2 (28) , the cell cycle phase in which tumor cells are most sensitive to damage by cisplatin and doxorubicin (30) (31) (32) . Depending on the cell type, DFMO arrests cells in either G1 or G2 (27, (50) (51) (52) . Our observations are more consistent with a G2 arrest in response to ODC and DFMO treatment, since this is the phase when cells are most sensitive to genotoxic damage.
Targeting ODC and polyamine synthesis is an attractive antitumor target since high levels of polyamines have been measured in multiple tumor types, and are necessary for transformation and progression (14, 17, 22) . DFMO is approved for treatment of trypanosomiasis and facial hirsutism, and is in clinical trials for treatment or prevention of various tumor types (22) . DFMO is of particular chemotherapeutic interest in MYCN-amplified neuroblastoma, where Myc-driven overexpression of ODC contributes to tumor hyperproliferation (24) . At the time of this study, the only studies of DFMO in combination with genotoxic chemotherapies are in brain tumors, and presently there are no clinical trials in breast cancer using DFMO as single agent therapy or in combination with other drugs. Clinical trials in the late 1990's established that DFMO reduces polyamines in breast cancer patients, but it did not reduce tumor burden as a single agent (53, 54) . Application of DFMO in combination with doxorubicin to TNBC models in pre-clinical models would lend further support for the efficacy of this combination, with likely promise due to the apparent low toxicity of DFMO. Combining DFMO with genotoxic chemotherapies could also be effective in other tumor types with elevated ODC activity or expression, including melanoma, esophageal, prostate, and colorectal cancers (28, (55) (56) (57) .
The pronounced effects of DFMO as a single agent on TNBC cell viability ( Fig. 9 , F and G) indicate that this molecular subtype of breast cancer is especially reliant on de novo polyamine biosynthesis, since in many other cell types, targeting polyamine synthesis is not effective unless combined with a polyamine uptake inhibitor (15) . While the specific polyamine transport mechanisms are not well defined (22) , it will be interesting to investigate the expression and function of polyamine transporters in TNBC, as deficiencies in transport systems may contribute to a more pronounced reliance on intracellular biosynthesis. Further characterization of polyamine metabolism and the effects of DFMO treatment in TNBC will help identify why this subtype is particularly sensitive.
To our knowledge, this is the first study to profile metabolic changes in response to DFMO in breast cancer. Adding exogenous polyamines or thymidine was insufficient to rescue the effects of DFMO in TNBC (Fig. 6 ). Importantly, it is evident that treatment of TNBC cells with DFMO also affects metabolites outside of polyamine metabolism, related to nucleotide, onecarbon, and other amino acid metabolism. While in colon tumor cells the effects of DFMO were the result of depleting SAM and nucleotide pools and could be reversed with exogenous thymidine (33) , this was not the case in TNBC cells (Fig. 6 ). Since TNBC cells are more sensitive to DFMO than non-TNBC cells, this implies that an intrinsic genetic or epigenetic property of TNBC renders these tumors more susceptible to ODC inhibition, at least in vitro.
Whether this represents a metabolic vulnerability in TNBC that can be exploited therapeutically remains to be determined, but given the efficacy of DFMO used in other indications, this warrants exploration in pre-clinical models.
In summary, we have identified changes in arginine and polyamine metabolism in TNBC cells exposed to chemotherapy, due to a decrease of the polyamine synthesis enzyme ODC. By targeting ODC with the inhibitor DFMO, we show that we can sensitize TNBC cells to doxorubicin. Further studies on the mechanisms linking genotoxic damage to ODC degradation, mechanisms of sensitization, and evaluation of combinations in pre-clinical models will provide additional insight for eventual therapeutic applications.
Experimental procedures
Cell culture SUM-159PT and SUM-149PT cells were obtained from Asterand Bioscience; all other cell lines were obtained from the ATCC. Cell lines were authenticated using short tandem repeat profiling, and no cell lines used in this study were found in the database of commonly misidentified cell lines, which is maintained by the International Cell Line Authentication Committee and National Center for Biotechnology Information BioSample. All cells were maintained in RPMI medium (Wisent Bioproducts) containing 10% FBS (Gibco). Cells were passaged for no more than 4 months and routinely assayed for mycoplasma contamination.
Chemotherapy agents and inhibitors
Doxorubicin was purchased from Cell Signaling Technology and dissolved in DMSO at 10mM; DL-α-Difluoromethylornithine (hydrochloride hydrate) was purchased from Cayman Chemical and dissolved in DMSO at 50mM; spermidine, thymidine, and aminoguanidine hydrochloride were purchased from Sigma and dissolved in water at 10mM,100mM or 1M, respectively; putrescine (dihydrochloride) was purchased from Santa Cruz Biotechnology and dissolved in water at 10mM; N-ω-Hydroxy-L-norarginine acetate salt was purchased from Bachem and dissolved in water at 50mg/mL. Cisplatin was obtained from the Dana Farber Cancer Institute pharmacy at 1mg/mL in PBS. DMSO for use as an organic solvent and vehicle control was purchased from Fisher Scientific.
Antibodies ODC (MABS36, 1:100) was purchased from Millipore. ARG2 (ab137069, 1:1000) was purchased from Abcam. pH2A.X S139 (9718, 1:1000), beta-actin (4970, 1:1000), c-Myc (5605, 1:1000), and vinculin (13901, 1:1000) were purchased from Cell Signaling Technology. Antibodies were used at indicated dilutions in 5% milk (Andwin Scientific) in TBST buffer (Boston Bioproducts), except for p-H2A.X in 5% BSA (Boston Bioproducts) in TBST.
LC/MS-MS metabolomics profiling
Cells were maintained in RPMI + 10% FBS, and fresh medium was added at the time cells were treated. For metabolite extraction, medium was aspirated and ice-cold 80% (v/v) methanol was added. Cells and the metabolite-containing supernatants were collected. Insoluble material was pelleted by centrifugation at 20,000 g for 5 minutes. The resulting supernatant was evaporated under nitrogen gas. Samples were resuspended using 20 µL HPLC-grade water for mass spectrometry. For polar metabolite profiling, five microliters from each sample were injected and analyzed using a 5500 QTRAP hybrid triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) with HILIC chromatography (Waters Amide XBridge) via selected reaction monitoring (SRM) with polarity switching. A total of 293 endogenous water-soluble metabolites were targeted for steady-state analyses. Electrospray source voltage was +4950 V in positive ion mode and −4500 V in negative ion mode. The dwell time was 3 ms per SRM transition (58) . Peak areas from the total ion current for each metabolite were integrated using MultiQuant v2.1.1 software (AB/SCIEX). For 13 C-labeled experiments, five microliters from each sample (20 uL) were injected with similar methodology as above using a 6500 QTRAP (AB/SCIEX) and integrated using MultiQuant v3.0 software (59) . SRMs were created for expected 13 C incorporation in various forms. Metabolite total ion counts were the integrated total ion current from a single SRM transition and normalized by cellular protein content. Nonhierarchical clustering was performed by Metaboanalyst 4.0 using a Euclidean distance measure and Ward's clustering algorithm (60) .
Polyamine concentration determinations and ODC activity assays
Cells were washed with PBS and harvested in ODC breaking buffer (25mM Tris-HCl (pH 7.5), 0.1mM EDTA, 2.5mM DTT). Intracellular polyamine concentrations of cell lysates were determined by HPLC following acid extraction and dansylation of the supernatant, as originally described by Kabra et al. (61) . Standards prepared for HPLC included diaminoheptane (internal standard), PUT, SPD, and SPM, all of which were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Enzyme activity assays were performed for ODC using radiolabeled substrates, as previously described (62) . All enzyme activities and intracellular polyamine concentrations are presented relative to total cellular protein, as determined using Bio-Rad protein dye (Hercules, CA) with interpolation on a bovine serum albumin standard curve.
Isotope labeling
RPMI powder lacking glutamine, arginine, tryptophan, and glucose was obtained from US Biological Life Sciences and supplemented with 25 µM L-tryptophan (Sigma-Aldrich), 11.1mM D-glucose (Gibco), and 10% dialyzed FBS (Gibco). For arginine labeling, 2mM glutamine (Gibco) and 1.1mM L-arginine-13 C6 hydrochloride (Aldrich) were added; for glutamine labeling, 2mM L-glutamine-13 C5 (Cambridge Isotope Laboratories) and 1.1mM L-arginine hydrochloride (Sigma) were added. Labeled medium, with or without chemotherapy agents, was added to cells, and cellular metabolites were extracted as described above after 48 hours.
Immunoblotting
Cells were washed with ice-cold PBS (Boston Bioproducts) and lysed in radioimmunoprecipitation buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), protease inhibitor cocktail, 50 nM calyculin A, 1mM sodium pyrophosphate, and 20 mM sodium fluoride) for 15 min at 4°C. Cell extracts were cleared by centrifugation at 14,000 rpm for 10 min at 4°C, and protein concentration was measured with the Bio-Rad DC protein assay. Lysates were resolved on acrylamide gels by SDS-PAGE and transferred electrophoretically to nitrocellulose membrane (Bio-Rad) at 100 V for 90 min. Blots were blocked in TBS buffer (10 mmol/L Tris-HCl, pH 8, 150 mmol/L NaCl, Boston Bioproducts) containing 5% (w/v) nonfat dry milk (Andwin Scientific). Membranes were incubated with nearinfrared dye-conjugated IRDye 800CW secondary antibodies (LiCor, 1:20,000 in 5% milk-TBST) and imaged on a LiCor Odyssey CLx.
Quantitative real-time polymerase chain reaction
Total RNA was isolated with the NucleoSpin RNA Plus (MACHEREY-NAGEL) according to the manufacturer's protocol. Reverse transcription was performed using the TaqMan Reverse Transcription Reagents (Applied Biosciences). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using a CFX384 Touch Real-Time PCR Detection System (Bio-Rad). Quantification of mRNA expression was calculated by the DCT method with 18S ribosomal RNA as the reference gene.
RNA interference siRNA ON-TARGETplus SMARTpools against human ODC1 (L-006668-00), OAZ1 (L-019216-00), and Myc (L-003282-02) were purchased from Dharmacon and dissolved in siRNA buffer (Dharmacon). Cells were transfected with Lipofectamine RNAiMAX Reagent (Invitrogen) in Opti-MEM (Gibco) according to the manufacturer's protocol (Invitrogen MAN0007825), with a final concentration of 20nM siRNA and 3µL/mL Lipofectamine.
Propidium iodide viability assay
Cell viability was assayed with a propidium iodide-based plate-reader assay, as previously described (63) . Briefly, cells in 96-well plates were treated with a final concentration of 30mM propidium iodide (Cayman Chemical) for 20 min at 37°C. The initial fluorescence intensity was measured in a GENios FL (Tecan) at 560nm excitation/635nm emission. Digitonin (Millipore) was then added to each well at a final concentration of 600mM. After incubating for 20 min at 37°C, the final fluorescence intensity was measured. The fraction of dead cells was calculated by dividing the background-corrected initial fluorescence intensity by the final fluorescence intensity. Viability was calculated by (1 -fraction of dead cells).
Sulforhodamine B growth assay
Population size as cell confluency was assayed by sulforhodamine B staining, as previously described (64) . Briefly, cells in 96-well plates were fixed in 8.3% final concentration of tricarboxylic acid of 1 hour at 4°C, washed three times with water, and stained for 30 minutes with 0.5% sulforhodamine B in 1% acetic acid. Plates were washed 3 times with 1% acetic acid and dye was solubilized in 10mM Tris pH 10.5 before measuring absorbance at 510nm on an Epoch plate reader (BioTek). Relative growth was determined as (treatment absorbance / control absorbance) following 72 hours of growth. Doubling time was determined by fitting an exponential growth equation to population sizes over four days.
Analysis of public data
Data from METABRIC and CCLE were accessed through cBioPortal, www.cbioportal.org. Data was analyzed using MATLAB R2017b and Prism 7. 
Statistics and reproducibility
